Research Remains Focused on Bringing CAR T-Cell Therapy to Solid Tumors

Mark Leick, MD, discusses how the emergence of CAR T-cell therapies have affected the treatment paradigms in various hematologic malignancies, expands on how persisting challenges with the use of this type of treatment are being addressed, and details research into the use of CAR T-cell therapy in patients with solid tumors.

Related Keywords

Massachusetts , United States , Boston , Mark Leick , Groupc Monthly , Harvard Medical School , Research Institute , Mass General Research Institute , Massachusetts General Hospital , Cart Cell Therapy , Solid Tumors , Hematologic Malignancies , Lymphoma ,